MedPath

Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women

Early Phase 1
Completed
Conditions
Pregnancy Related
Pertussis
Interventions
Biological: Tdap vaccine
Registration Number
NCT03498300
Lead Sponsor
Mahidol University
Brief Summary

This study evaluated the seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women.

All seronegative participants received Tdap, while seropositive participants were equally randomized into 2 groups. Half of seropositive participants received Tdap and the other half received tetanus-diphtheria (Td) as standard protocol.

Detailed Description

The primary objective of this study was to determine the seroprevalence of anti-pertussis toxin antibodies (anti-PT IgG) among pregnant Thai women. The secondary objectives were to evaluate antibody response after Tdap vaccination between seronegative and seropositive participants and to compare the different antibody titers at delivery among seropositive participants who received Tdap to those who received tetanus-diphtheria vaccine (Td). The sample size calculation was based on the primary objective. Randomized clinical trial was performed for the latter secondary objective.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
129
Inclusion Criteria
  • Thai pregnant women age at least 18 years
  • No known underlying disease
  • Singleton pregnancy without maternal or fetal complications
  • Gestational age not more than 20 weeks at the time of recruitment
  • Desired for delivery at Siriraj Hospital
Read More
Exclusion Criteria
  • Pregnant women who have any contraindication to Tdap vaccine including

    1. History of serious allergic reaction to any components of Tdap vaccine
    2. History of seizure or coma after receiving Tdap vaccine in childhood
    3. Having an underlying disease involving central nervous system (e.g., epilepsy, Guillain-Barré syndrome)
  • History of serious reactions after receiving Tdap vaccine (e.g., severe pain, severe swelling at the injection site)

  • Recently had Tdap vaccine injection

  • Denied for Tdap vaccine injection

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ExperimentalTdap vaccineA single dose of Tdap vaccine at GA 27 - 36 weeks
Primary Outcome Measures
NameTimeMethod
The Seroprevalence of Anti-pertussis Toxin Antibodies (Anti-PT IgG) in Pregnant Thai WomenFour months

Percentage of participants who were seropositive for anti-pertussis toxin antibodies (anti-PT IgG).

The overall number of 129 participants is greater than the number of 42 participants include in the Particiant Flow Module because it was the sample size calculated based on the primary objective, which was the seroprevalence of anti-pertussis antibodies in pregnant Thai women. Randomized clinical trial on 42 seropositive participants was performed for one of the secondary objectives, which was to compare the different anti-PT IgG at delivery among seropositive participants who received Tdap to those who received Td.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline in Anti-pertussis Toxin Immunoglobulin G Levels Among Seropositive Participants Who Received Tdap to Those Who Received TdEight months

Trial Locations

Locations (1)

Nalat Sompagdee

🇹🇭

Bangkok Noi, Bangkok, Thailand

© Copyright 2025. All Rights Reserved by MedPath